Resisting TB

A study finds that drug-resistant tuberculosis is more prevalent than current estimates suggest.

Written byCristina Luiggi
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

A study of more than 1,200 adults worldwide reveals that the prevalence of tuberculosis (TB) strains that are resistant to both first- and second-line treatments is higher than previously realized. Extensively drug-resistant tuberculosis strains were detected in 6.4 percent of all samples analyzed, according to the results of the study, published online yesterday (August 29) in The Lancet, with some countries, such as South Korea, having a prevalence of around 15 percent.

Strains resistant to second-line treatments—those administered after initial treatments have failed—were found in 44 percent of the patients, with some countries such as Latvia having patient populations where as high as 62 percent of infections were resistant.

“Most international recommendations for TB control have been developed for MDR [multidrug-resistant] TB prevalence of up to around 5 percent,” Sven Hoffner, Associate Professor at the Swedish Institute for Communicable Disease Control, wrote in an accompanying comment. “Yet now we face ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies